Psoriasis Global Markets Report 2023: Methotrexate, Ciclosporin, and Acitretin - A $34.5 Billion Market by 2027 - Long-term Forecast to 2032

DUBLIN, Feb. 27, 2023 /PRNewswire/ -- The "Psoriasis Global Market Report 2023" report has been added to  ResearchAndMarkets.com's offering.

Major players in the psoriasis market are AbbVie Inc., Pfizer Inc., Novartis, Eli Lilly and Company, Celgene Corporation, Johnson & Johnson, Amgen Inc., Boehringer Ingelheim GmbH, Merck & Co Inc. and Janssen Biotech.

The global psoriasis market will grow from $20.31 billion in 2022 to $22.80 billion in 2023 at a compound annual growth rate (CAGR) of 12.3%. The psoriasis market is expected to grow to $34.50 billion in 2027 at a CAGR of 10.9%.

The psoriasis market consists of sales of Methotrexate, Ciclosporin, and Acitretin. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Psoriasis refers to a skin condition that typically affects the knees, elbows, trunk, and scalp and results with a rash with itchy, scaly spots. The primary contributing factor may be an immune system issue wherein infection-fighting cells unintentionally kill healthy skin cells.

North America is the largest region in the psoriasis market in 2022. Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the psoriasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The main classes of drugs in psoriasis are interleukin inhibitors, corticosteroids, anti-inflammatory, and tumor necrosis factor inhibitors. Corticosteroids are a group of steroid hormones generated by vertebrates' adrenal cortex and are also synthetic equivalents of these hormones.

The different types of drugs include small molecules and biologics and involve various disease indications such as plaque psoriasis, nail psoriasis, guttate psoriasis, pustular psoriasis, and erythrodermic psoriasis. The several routes of administration include oral, topical, injectable, and distributed through hospitals, retail pharmacies, and e-commerce.

The rise in the prevalence of psoriasis patients is driving the Psoriasis market. Psoriasis is caused due to immune system, genetics, and environment. The rise in psoriasis patients in the past few years can be mainly attributed to climate change, stress, and an unhealthy lifestyle. According to the World Psoriasis Day consortium, 125 million people globally - 2 to 3 percent of the total population have psoriasis. Therefore, the rise in the prevalence of psoriasis patients is expected to propel the growth of the psoriasis over coming years.

The high cost of psoriasis therapy is expected to restrain the growth of the psoriasis market over the coming years. For instance, according to a report published by WebMD, a US-based publication agency, disease-modifying antirheumatic medication (DMARD) used to treat PsA can cost between $1,500 and $2,000 per year. In the US, a dermatologist office visit typically costs $150 to $200. The high cost is because patent protections are preventing many alternative drugs. Therefore, the high cost of psoriasis therapy hampers the growth of the psoriasis market.

Combination therapy is an emerging trend in the psoriasis market. Combination therapy is an f treatment that combines two different psoriasis treatments at the same time. When two drugs with different mechanisms of action are combined (combination therapy), the effect is greater than that obtained by monotherapy (treatment with a single drug).

Studies suggest that combination therapy eases psoriasis symptoms more effectively than a single therapy and has lesser side effects. An example of combination therapy for the treatment of active psoriatic arthritis (PsA) is taltz (ixekizumab) with methotrexate developed by Eli Lilly and Company.

The process of approval of psoriasis drugs is becoming easier globally. This is evident from the increasing approvals of drugs for psoriasis in recent years. Some of the examples include the first regulatory approval of SKYRIZI (risankizumab) for the treatment of plaque psoriasis in Japan, and the Center for Drug Evaluation and Research approved Avsola (infliximab-axxq) for the treatment of plaque psoriasis. Hence, the increasing ease of drug approvals is expected to drive the psoriasis drugs market in the coming years.

The countries covered in the psoriasis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

A selection of companies mentioned in this report includes

• AbbVie Inc.
• Pfizer Inc.
• Novartis
• Eli Lilly and Company.
• Celgene Corporation
• Johnson & Johnson
• Amgen Inc.
• Boehringer Ingelheim GmbH
• Merck & Co. Inc.
• Janssen Biotech Inc.
• Takeda Pharmaceutical Company Limited
• Stiefel Laboratories Inc.
• AstraZeneca
• UCB
• Sun Pharmaceutical Industries Ltd.
• Forward Pharma
• Almirall
• Valeant Pharmaceuticals
• Biogen Idec
• Biocon
• Celltrion Inc.
• Dr.Reddy's Laboratories

Key Topics Covered:

1. Executive Summary

2. Psoriasis Drugs Market Characteristics

3. Psoriasis Drugs Market Trends And Strategies

4. Psoriasis Drugs Market - Macro Economic Scenario
4.1 COVID-19 Impact On Psoriasis Drugs Market
4.2 Ukraine-Russia War Impact On Psoriasis Drugs Market
4.3 Impact Of High Inflation On Psoriasis Drugs Market

5. Psoriasis Drugs Market Size And Growth
5.1. Global Psoriasis Drugs Historic Market, 2017-2022, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Psoriasis Drugs Forecast Market, 2022-2027F, 2032F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market

6. Psoriasis Drugs Market Segmentation
6.1. Global Psoriasis Drugs Market, Segmentation By Drug class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

• Interleukin Inhibitors
• Corticosteroids
• Anti-Inflammatory
• Tumor Necrosis Factor Inhibitor

6.2. Global Psoriasis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

• Hospitals
• Retail Pharmacies
• E-Commerce

6.3. Global Psoriasis Drugs Market, Segmentation By Drug Types, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

• Small molecules
• Biologics 4

6.4. Global Psoriasis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

• Oral
• Tropical
• Injectable

6.5. Global Psoriasis Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

• Plaque Psoriasis
• Nail Psoriasis
• Guttate Psoriasis
• Pustular Psoriasis
• Erythrodermic Psoriasis

7. Psoriasis Drugs Market Regional And Country Analysis
7.1. Global Psoriasis Drugs Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
7.2. Global Psoriasis Drugs Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

For more information about this report visit https://www.researchandmarkets.com/r/gyfy4m-global?w=5

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]
 
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
 
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets